| CAS NO: | 141400-58-0 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 188.31 |
|---|---|
| Formula | C7H12N2S2 |
| CAS No. | 141400-58-0 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 38 mg/mL (201.8 mM) |
| Water: <1 mg/mL | |
| Ethanol: 38 mg/mL (201.8 mM) | |
| Other info | Chemical Name:
2-(sec-butyldisulfanyl)-1H-imidazole. InChi Key: BPBPYQWMFCTCNG-UHFFFAOYSA-N InChi Code: InChI=1S/C7H12N2S2/c1-3-6(2)10-11-7-8-4-5-9-7/h4-6H,3H2,1-2H3,(H,8,9) SMILES Code: CCC(SSC1=NC=CN1)C |
| Synonyms | PX12; PX 12; PX-12 |
| In Vitro | In vitro activity: In MCF-7 and HT-29 cells, PX-12 prevents the hypoxia (1% oxygen)-induced increase in HIF-1alpha protein, and decreases HIF-1-trans-activating activity, VEGF formation, and inducible nitric oxide synthase. PX-12 also inhibits the growth of MCF-7 and HT-29 cells with IC50s of 1.9 μM and 2.9μM, respectively. PX-12 also inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase. In A549 cells, PX-12 inhibits cell growth via G2/M phase arrest, and Bax-mediated and ROS-dependent apoptosis. In hepatocelluar carcinoma cells, PX-12 exerts a synergistic effect with 5-FU to significantly suppress tumorigenicity. Cell Assay: Cell growth is measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cells are exposed to a range of concentrations of PX-12 or pleurotin for 16 h in air or hypoxia (1% oxygen). The cells are then washed with warm drug-free medium and grown in air for the remainder of the 72-h incubation. |
|---|---|
| In Vivo | In mice bearing MCF-7 tumor xenografts, PX-12 (12 mg/kg, i.p.) decreases HIF-1α and VEGF protein levels and microvessel density. |
| Animal model | Mice bearing MCF-7 tumor xenografts |
| Formulation & Dosage | Dissolved in 0.01 N HCl, polyethylene glycol-400 (2.0 mg/ml); 12 mg/kg; i.p. |
| References | Mol Cancer Ther. 2003 Mar;2(3):235-43; Cancer Chemother Pharmacol. 2011 Aug;68(2):405-13. |
m.cnreagent.com